Get started
Author

Ayako Tanaka

Observed names: A. Tanaka, AYAKO TANAKA, Tanaka, Ayako
Observed institutions: Tokyo Medical University, National Cancer Centre Japan, National Cancer Center Hospital, Osaka Prefectural Hospital Organization, Osaka Habikino Medical Center, National Cancer Center Hospital, Nagoya University
ORCID: 0009-0009-1915-1400
Observed ORCID: 0009-0009-1915-1400
OpenAlex ID: A5035744584
Pretreatment advanced lung cancer inflammation index ( ALI ) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
2017 · Takayuki Shiroyama, Hidekazu Suzuki, et al. · Cancer Medicine · 116
PDF
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
2016 · S. Kanda, K. Goto, et al. · Annals of Oncology · 95
Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status
2013 · Yoshio Ohno, Jun Nakashima, et al. · International Journal of Clinical Oncology · 59
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents
2018 · So Takata, Genju Koh, et al. · Journal of Infection and Chemotherapy · 53
Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer
2018 · TAKAYUKI SHIROYAMA, HIDEKAZU SUZUKI, et al. · Anticancer Research · 52
PDF
Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer
2019 · SHINGO NASU, NORIO OKAMOTO, et al. · Anticancer Research · 49
PDF
The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
2019 · TOMONORI HIRASHIMA, TOMOHIRO KANAI, et al. · Anticancer Research · 47
PDF
Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study
2018 · Tomonori Hirashima, Yoshitaka Tamura, et al. · BMC Cancer · 39
PDF
The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer
2020 · YOSHIMI NODA, HIDEKAZU SUZUKI, et al. · Anticancer Research · 34
PDF
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
2017 · Shingo Satoh, Takayuki Shiroyama, et al. · Respiratory Medicine Case Reports · 27
PDF
Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors
2020 · TOMOHIRO KANAI, HIDEKAZU SUZUKI, et al. · Anticancer Research · 21
PDF
Radial endobronchial ultrasound with a guide sheath for diagnosis of peripheral cavitary lung lesions: a retrospective study
2016 · Manabu Hayama, Norio Okamoto, et al. · BMC Pulmonary Medicine · 20
PDF
Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
2020 · Yumiko Samejima, Atsuhiko Iuchi, et al. · Internal Medicine · 19
PDF
Factors predicting incisional surgical site infection in patients undergoing open radical cystectomy for bladder cancer
2013 · Tatsuo Gondo, Yoshio Ohno, et al. · International Journal of Clinical Oncology · 19
Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients
2021 · TOMONORI HIRASHIMA, YOSHIMI NODA, et al. · Anticancer Research · 16
PDF
Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC HarboringEGFRT790M
2018 · KENTARO MASUHIRO, TAKAYUKI SHIROYAMA, et al. · Anticancer Research · 13
PDF
Transformation to small cell lung cancer after first-line afatinib treatment
2018 · Takayuki Shiroyama, Shingo Nasu, et al. · Respiratory Medicine Case Reports · 13
PDF
Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis
2019 · Atsushi Sekiya, Shiro Suzuki, et al. · International Journal of Oncology · 12
PDF
Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
2016 · Takayuki Shiroyama, Manabu Hayama, et al. · Respiratory Medicine Case Reports · 12
PDF
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study
2020 · Shingo Nasu, Hidekazu Suzuki, et al. · Investigational New Drugs · 11
The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer.
2015 · Norio Okamoto, Hidekazu Suzuki, et al. · PubMed · 10
Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
2018 · Shingo Nasu, Takayuki Shiroyama, et al. · Internal Medicine · 9
PDF
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
2018 · Motohiro Tamiya, Hidekazu Suzuki, et al. · Investigational New Drugs · 9
Skin Rash Can Be a Useful Marker for Afatinib Efficacy
2018 · SHINGO NASU, HIDEKAZU SUZUKI, et al. · Anticancer Research · 9
PDF
External Validation of Preoperative Nomograms Predicting Biochemical Recurrence after Radical Prostatectomy
2013 · A. Tanaka, M. Ohori, et al. · Japanese Journal of Clinical Oncology · 9
Works count: 56
Citation count: 845
H-index: 15
I10-index: 21
Year
Topic
Type